EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Osteocytes in the Metastatic Bone Niche: Mechanistic Pathways and Therapeutic Targets

Alhomam Dabaliz iD, Mohamad Bakir iD, Lana Fatash, Mais Aldoush, Khalid Said Mohammad iD

Pharmaceuticals · 20.04.2026 · 19 (4) · 644

DOI: 10.3390/ph19040644 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 20.04.2026. Verfasst von Alhomam Dabaliz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Skills, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 224 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteocytes, once viewed mainly as passive bone-embedded cells, are now recognized as active regulators of the metastatic bone niche. Emerging evidence indicates that these cells integrate mechanical, inflammatory, and tumor-derived cues to influence metastatic seeding, dormancy, reactivation, and lesion progression in bone. This review synthesizes current understanding of osteocyte contributions to skeletal metastasis. We discuss core signaling axes, including osteocyte-derived RANKL/OPG balance, Wnt antagonists (sclerostin/DKK1), mechanotransduction pathways (Piezo1 signaling and connexin-43 hemichannels), and osteocyte paracrine mediators (extracellular vesicles and senescence-associated factors), and examine how each axis modulates tumor cell dormancy, osteolysis, or osteoblastic progression. We then review translational strategies targeting osteocytes, recent preclinical and clinical insights. Emerging biomarkers (e.g., serum sclerostin, DKK1, bone turnover markers) and immune–skeletal imaging approaches are also considered. Controversies, including the paradoxical effects of sclerostin blockade and the identity of in vivo RANKL sources, are discussed. Finally, we outline key knowledge gaps and propose endpoints for future trials. In summary, an osteocyte-centric perspective reveals novel targets and strategies for managing bone metastases, guiding future translational research.

Schlagwörter

Stichwörter der Autor:innen

bone metastasismechanotransductionmetastatic nicheosteocytessclerostin (SOST)targeted therapy

Autor:innen und Institutionen

  • Department of Clinical Skills, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
  • Department of Medicine, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
  • Department of Anatomy, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.

ORCID-Profile: Alhomam Dabaliz, Mohamad Bakir, Khalid Said Mohammad

Zitieren

APA

Dabaliz, A., Bakir, M., Fatash, L., Aldoush, M., & Mohammad, K. S. (2026). Osteocytes in the Metastatic Bone Niche: Mechanistic Pathways and Therapeutic Targets. Pharmaceuticals, 19(4), 644. https://doi.org/10.3390/ph19040644

Vancouver

Dabaliz A, Bakir M, Fatash L, Aldoush M, Mohammad KS. Osteocytes in the Metastatic Bone Niche: Mechanistic Pathways and Therapeutic Targets. Pharmaceuticals. 2026;19(4):644. doi:10.3390/ph19040644

BibTeX
@article{Dabaliz2026,
  author = {Dabaliz, Alhomam and Bakir, Mohamad and Fatash, Lana and Aldoush, Mais and Mohammad, Khalid Said},
  title = {Osteocytes in the Metastatic Bone Niche: Mechanistic Pathways and Therapeutic Targets},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {4},
  pages = {644},
  doi = {10.3390/ph19040644}
}
Kostenlos starten →